Skip to content

Efficacy and safety of Intestinal bacteria capsule for the Treatment of refractory Diarrhea-Predominant Irritable Bowel Syndrome

Efficacy and safety of Fecal Microbiota Transplantation for the Treatment of refractory Diarrhea-Predominant Irritable Bowel Syndrome

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17013457
Enrollment
Unknown
Registered
2017-11-20
Start date
2017-11-20
Completion date
Unknown
Last updated
2017-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

refractory diarrhea-predominant irritable bowel syndrome

Interventions

A:FMT
B:probiotics

Sponsors

The Affiliated Third Hospital of Army Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1) male or female, aged 16 to 60; 2) in accordance with irritable bowel syndrome diagnostic criteria of the Roman ?, patients are diagnosised Diarrhea-Predominant Irritable Bowel Syndrome; 3) the patients were diagnosedDiarrhea-Predominant Irritable Bowel Syndrome more than 3 months,and they have used conventional drug treatment,but no obvious obvious effect or break out repeatedly; 4) no other serious disease, mental disorders, and have ability of normal communication; 5) signed informed consent, agreed to participate in the study.

Exclusion criteria

Exclusion criteria: 1) complicated with other serious heart, liver, kidney, respiratory, digestive, blood, endocrine system disease; 2) with double infection of the gut, such as CDI, enterohemorrhagic escherichia coli, salmonella, hayes bacteria, campylobacter, plague, and cytomegalovirus; 3) abnormal liver function or any of the following history of liver disease: 2 times higher than normal amount of AST and ALT limit, liver cirrhosis, hepatic encephalopathy history, history of esophageal varices or portal vein shunt; 4) abnormal kidey function or the following kidney disease: serum creatinine:> 1.5 times normal limit; The history of dialysis; history of nephrotic syndrome; 5) concurrence various acute infection, tumor, and serious arrhythmia, mental system disorders, drug or alcohol addiction; 6) Unable to complete the site visit, or the various factors influencing the compliance.

Design outcomes

Primary

MeasureTime frame
Abdominal pain score;number of diarrhoea and BSFS;

Countries

China

Contacts

Public ContactChen Dongfong

The Affiliated Third Hospital of Army Medical University

chendf1981@126.com+86 17729658759

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026